{"id":579432,"date":"2026-08-09T11:44:13","date_gmt":"2026-08-09T11:44:13","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/579432\/"},"modified":"2026-08-09T11:44:13","modified_gmt":"2026-08-09T11:44:13","slug":"veliparib-mechanism-dose-administration-and-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/579432\/","title":{"rendered":"Veliparib: Mechanism, Dose, Administration, And Clinical Trials"},"content":{"rendered":"<p>Veliparib is an investigational oral poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, studied primarily with platinum chemotherapy in ovarian cancer, breast cancer, lung cancer, and other solid tumors.<\/p>\n<p>Veliparib is not approved by the US Food and Drug Administration or European Medicines Agency. Its most important Phase 3 programs evaluated veliparib with carboplatin and paclitaxel, followed by maintenance veliparib.<\/p>\n<p>What Is Veliparib?<\/p>\n<p>Veliparib is an oral small-molecule inhibitor of PARP1 and PARP2, enzymes that help cancer cells repair damaged DNA.<\/p>\n<p>PARP inhibition prevents efficient repair of single-strand DNA breaks. During DNA replication, unrepaired damage develops into more serious double-strand breaks. Tumors with deficient homologous recombination repair, including some cancers with BRCA1 or BRCA2 mutations, are particularly vulnerable to this process.<\/p>\n<p>Veliparib has relatively limited PARP-trapping activity compared with some other PARP inhibitors. Its development therefore focused heavily on combining PARP inhibition with DNA-damaging chemotherapy.<\/p>\n<p>Veliparib was previously known as ABT-888.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-544225\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/Zotatifin-OncoDaily-3-800x450.webp\" alt=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials\" width=\"800\" height=\"450\" title=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials 2\"  \/><\/p>\n<p>What Is The Dose Of Veliparib?<\/p>\n<p>There is no approved veliparib dose because the drug remains investigational.<\/p>\n<p>The principal regimen used in the Phase 3 BROCADE3 breast cancer trial was:<\/p>\n<p>Veliparib 120 mg orally twice daily on Days \u22122 through 5 of each 21-day chemotherapy cycle.<\/p>\n<p>Veliparib was administered with carboplatin and paclitaxel. Patients who discontinued chemotherapy could continue veliparib at 300 mg twice daily, with escalation to 400 mg twice daily when tolerated.<\/p>\n<p>The Phase 3 VELIA ovarian cancer trial used:<\/p>\n<p>150 mg orally twice daily continuously during six 21-day cycles of carboplatin and paclitaxel<br \/>\nFollowed by 300 mg twice daily, increasing to 400 mg twice daily when tolerated, during maintenance treatment<\/p>\n<p>These are clinical-trial regimens rather than approved prescribing recommendations.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-544226\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/Zotatifin-OncoDaily-1-1-800x450.webp\" alt=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials\" width=\"800\" height=\"450\" title=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials 3\"  \/><\/p>\n<p>How Is Veliparib Administered?<\/p>\n<p>Veliparib is taken orally as capsules rather than administered by intravenous infusion or injection.<\/p>\n<p>Depending on the clinical-trial protocol, veliparib was administered either:<\/p>\n<p>Intermittently around chemotherapy days<br \/>\nContinuously twice daily<br \/>\nAs maintenance treatment after chemotherapy<\/p>\n<p>Public trial records do not provide one universal instruction regarding administration with food, missed doses, vomiting after administration, or capsule handling. These instructions were determined by each study protocol.<\/p>\n<p>Does Veliparib Require An In-Line Filter?<\/p>\n<p>Veliparib does not require an in-line filter because it is taken orally.<\/p>\n<p>No dilution, infusion bag, intravenous tubing, or line-flushing procedure is required for veliparib itself. Separate preparation and filtration instructions apply to intravenous carboplatin, paclitaxel, or other combination treatments.<\/p>\n<p>Is Premedication Required?<\/p>\n<p>Veliparib does not have a standard drug-specific premedication regimen.<\/p>\n<p>Patients receiving carboplatin and paclitaxel require chemotherapy-related premedications, including antiemetics and agents used to reduce paclitaxel hypersensitivity reactions. Supportive treatment depends on the complete regimen rather than veliparib alone.<\/p>\n<p>Are Dose Reductions Used?<\/p>\n<p>Clinical trials permitted temporary interruption, dose reduction, or permanent discontinuation for toxicity.<\/p>\n<p>Dose modifications were commonly considered for:<\/p>\n<p>Thrombocytopenia<br \/>\nNeutropenia<br \/>\nAnemia<br \/>\nNausea or vomiting<br \/>\nFatigue<br \/>\nPersistent gastrointestinal toxicity<br \/>\nClinically important nonhematologic adverse effects<\/p>\n<p>In maintenance phases, escalation from 300 mg to 400 mg twice daily occurred only when the lower dose was tolerated.<\/p>\n<p>What Is Known About Veliparib Pharmacokinetics?<\/p>\n<p>Veliparib is orally bioavailable and was developed for twice-daily administration.<\/p>\n<p>Clinical pharmacokinetic studies supported the 120 mg twice-daily intermittent regimen used with carboplatin and paclitaxel in BROCADE3. Higher continuous doses of 300\u2013400 mg twice daily were used when veliparib was administered without concurrent chemotherapy.<\/p>\n<p>Complete approved guidance regarding metabolism, drug interactions, renal impairment, hepatic impairment, and food effects is unavailable because veliparib never received regulatory approval.<\/p>\n<p>Are Renal Or Hepatic Dose Adjustments Required?<\/p>\n<p>No validated renal- or hepatic-impairment dose recommendations have been established.<\/p>\n<p>Clinical studies generally required adequate kidney, liver, and bone-marrow function. Renal function was particularly relevant because patients frequently received platinum chemotherapy, which has its own organ-function requirements and dose-adjustment rules.<\/p>\n<p>What Did Clinical Trials Show?<\/p>\n<p>The Phase 3 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02470585\" target=\"_blank\" rel=\"noopener nofollow\">VELIA trial<\/a> evaluated veliparib with first-line carboplatin and paclitaxel, followed by veliparib maintenance, in advanced high-grade serous ovarian cancer.<\/p>\n<p>The veliparib-throughout regimen improved progression-free survival compared with chemotherapy alone, with the largest benefit observed among patients with BRCA-mutated or homologous recombination-deficient tumors. The combination also increased anemia, thrombocytopenia, nausea, and fatigue.<\/p>\n<p>The Phase 3 <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT02163694\" target=\"_blank\" rel=\"noopener nofollow\">BROCADE3 trial<\/a> evaluated veliparib with carboplatin and paclitaxel in HER2-negative advanced breast cancer with germline BRCA1 or BRCA2 mutations.<\/p>\n<p> Watch more: Learn about the Phase 3 BROCADE3 trial evaluating veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer.<\/p>\n<p>The addition of veliparib significantly improved progression-free survival. However, the final analysis did not establish a clear overall-survival advantage.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-544228\" src=\"https:\/\/www.newsbeep.com\/il\/wp-content\/uploads\/2026\/08\/Zotatifin-OncoDaily-2-1-800x450.webp\" alt=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials\" width=\"800\" height=\"450\" title=\"Veliparib: Mechanism, Dose, Administration, And Clinical Trials 4\"  \/><\/p>\n<p>Veliparib was also evaluated in lung cancer, glioblastoma, ovarian cancer, and other malignancies, but no study led to regulatory approval.<\/p>\n<p>Watch More: For an expert overview of the Phase 3 BROCADE3 trial, watch: <a href=\"https:\/\/ascopost.com\/videos\/esmo-2019-congress\/v%C3%A9ronique-di%C3%A9ras-on-brocade-3-results\/\" target=\"_blank\" rel=\"noopener nofollow\">V\u00e9ronique Di\u00e9ras, MD \u2013 BROCADE3 Phase 3 Trial (ESMO 2019)<\/a><\/p>\n<p>What Are The Side Effects Of Veliparib?<\/p>\n<p>Reported adverse effects include:<\/p>\n<p>Anemia<br \/>\nThrombocytopenia<br \/>\nNeutropenia<br \/>\nNausea<br \/>\nVomiting<br \/>\nFatigue<br \/>\nDiarrhea<br \/>\nReduced appetite<br \/>\nHeadache<\/p>\n<p>Hematologic toxicity became more prominent when veliparib was combined with carboplatin and paclitaxel. In VELIA, anemia and thrombocytopenia occurred more frequently with the veliparib-containing regimen than with chemotherapy alone.<\/p>\n<p>Read more about <a href=\"https:\/\/oncodaily.com\/insight\/33793\" rel=\"nofollow noopener\" target=\"_blank\">Paolo Tarantino: Final OS from BROCADE3 phase 3 trial<\/a> on OncoDaily.<\/p>\n<p>Mirna Antabian, MD<\/p>\n<p>                                                    &#13;<br \/>\n                                        FAQ&#13;<br \/>\n                                        &#13;<br \/>\n                                                                                            &#13;<br \/>\n                                                    Is Veliparib Approved?&#13;<\/p>\n<p>No. Veliparib remains investigational and has no FDA- or EMA-approved indication.<\/p>\n<p>&#13;<br \/>\n                                                &#13;<br \/>\n                                                                                            &#13;<br \/>\n                                                    Is Veliparib Chemotherapy?&#13;<\/p>\n<p>No. Veliparib is an oral targeted PARP1 and PARP2 inhibitor. It was frequently studied with chemotherapy.<\/p>\n<p>&#13;<br \/>\n                                                &#13;<br \/>\n                                                                                            &#13;<br \/>\n                                                    How Is Veliparib Taken?&#13;<\/p>\n<p>Veliparib is taken orally, usually twice daily. The exact dose and schedule depend on the clinical-trial regimen.<\/p>\n<p>&#13;<br \/>\n                                                &#13;<br \/>\n                                                                                            &#13;<br \/>\n                                                    Does Veliparib Require An Infusion Filter?&#13;<\/p>\n<p>No. Veliparib is an oral medication and does not require an in-line filter.<\/p>\n<p>&#13;<br \/>\n                                                &#13;<br \/>\n                                                                                            &#13;<br \/>\n                                                    What Cancers Was Veliparib Mainly Studied In?&#13;<\/p>\n<p>Its largest clinical programs involved advanced ovarian cancer and germline BRCA-mutated, HER2-negative advanced breast cancer.<\/p>\n<p>&#13;<br \/>\n                                                &#13;<br \/>\n                                                                                    &#13;<\/p>\n","protected":false},"excerpt":{"rendered":"Veliparib is an investigational oral poly(ADP-ribose) polymerase inhibitor, or PARP inhibitor, studied primarily with platinum chemotherapy in ovarian&hellip;\n","protected":false},"author":2,"featured_media":579433,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[163,85,46],"class_list":["post-579432","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-il","tag-israel"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/579432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=579432"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/579432\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/579433"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=579432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=579432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=579432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}